S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?

Viking Therapeutics (VKTX) Earnings Date, Estimates & Call Transcripts

$85.05
+46.57 (+121.02%)
(As of 02/27/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Apr. 24Estimated
Actual EPS
(Feb. 7)
-$0.25
Consensus EPS
(Feb. 7)
-$0.25
Skip Charts & View Estimated and Actual Earnings Data

VKTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VKTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Viking Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243($0.27)($0.25)($0.26)
Q2 20243($0.28)($0.22)($0.26)
Q3 20243($0.28)($0.23)($0.26)
Q4 20243($0.29)($0.28)($0.28)
FY 202412($1.12)($0.98)($1.06)

VKTX Earnings Date and Information

Viking Therapeutics last released its earnings data on February 7th, 2024. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). Viking Therapeutics has generated ($0.92) earnings per share over the last year (($0.92) diluted earnings per share). Earnings for Viking Therapeutics are expected to decrease in the coming year, from ($1.12) to ($1.40) per share. Viking Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 24th, 2024 based off prior year's report dates.

Viking Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/24/2024
Estimated)
------- 
2/7/2024Q4 2023($0.25)($0.25)-($0.25)--    
10/25/2023Q3 2023($0.22)($0.23)($0.01)($0.23)--    
7/26/2023Q2 2023($0.21)($0.19)+$0.02($0.19)--    
4/26/2023Q1 2023($0.24)($0.25)($0.01)($0.25)--
2/8/2023Q4 2022($0.23)($0.26)($0.03)($0.26)--
10/26/2022Q3 2022($0.23)($0.21)+$0.02($0.21)--
7/27/2022Q2 2022($0.21)($0.23)($0.02)($0.23)--
4/27/2022Q1 2022($0.20)($0.21)($0.01)($0.21)--    
2/9/2022Q4 2021($0.19)($0.16)+$0.03($0.16)--  
11/3/2021Q3 2021($0.21)($0.17)+$0.04($0.17)--    
7/28/2021Q2 2021($0.19)($0.20)($0.01)($0.20)--    
4/28/2021Q1 2021($0.18)($0.19)($0.01)($0.19)--  












Viking Therapeutics Earnings - Frequently Asked Questions

When is Viking Therapeutics's earnings date?

Viking Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 24th, 2024 based off last year's report dates. Learn more on VKTX's earnings history.

Did Viking Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) reported ($0.25) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.25). Learn more on analysts' earnings estimate vs. VKTX's actual earnings.

How can I listen to Viking Therapeutics's earnings conference call?

The conference call for Viking Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Viking Therapeutics's conference call transcript?

The conference call transcript for Viking Therapeutics's latest earnings report can be read online. Read Transcript

How much profit does Viking Therapeutics generate each year?

Viking Therapeutics (NASDAQ:VKTX) has a recorded net income of -$85.89 million. VKTX has generated -$0.92 earnings per share over the last four quarters.

What is Viking Therapeutics's EPS forecast for next year?

Viking Therapeutics's earnings are expected to decrease from ($1.12) per share to ($1.40) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:VKTX) was last updated on 2/28/2024 by MarketBeat.com Staff